The global status of research in breast cancer liver metastasis: a bibliometric and visualized analysis

References

• DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics. CA. 2019;2019(69):438–451.
   Google Scholar
• Bishop AJ, Ensor J, Moulder SL, et al. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer. 2015;121:4324–4332.
   PubMed Web of Science ®Google Scholar
• Jung KW, Won YJ, Kong HJ, et al. Survival of Korean adult cancer patients by stage at diagnosis, 2006-2010: national cancer registry study. Cancer Res Treat. 2013;45:162–171.
   PubMed Web of Science ®Google Scholar
• Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47(Suppl 3):S6–22.
   PubMed Web of Science ®Google Scholar
• Ruiz A, van Hillegersberg R, Siesling S, et al. Surgical resection versus systemic therapy for breast cancer liver metastases: results of a European case matched comparison. Eur J Cancer. 2018;95:1–10.
   PubMed Web of Science ®Google Scholar
• Gerratana L, Fanotto V, Bonotto M, et al. Pattern of metastasis and outcome in patients with breast cancer. Clin Exp Metastasis. 2015;32:125–133.
   PubMed Web of Science ®Google Scholar
• Sadot E, Lee SY, Sofocleous CT, et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: a case-control study with comparison to medically treated patients. Ann Surg. 2016;264:147–154.
   PubMed Web of Science ®Google Scholar
• Guler OC, Yildirim BA, Onal C. The impact of tumor volume in breast cancer liver metastasis patients treated with stereotactic radiotherapy – does size matter? Int J Radiat Oncol Biol Phys. 2020;108:e191–e2.
   Google Scholar
• Xiao YB, Zhang B, Wu YL. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis. J Zhejiang Univ Sci B. 2018;19:829–843.
   PubMed Web of Science ®Google Scholar
• Schrijver W, Suijkerbuijk KPM, van Gils CH, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110:568–580.
   PubMedGoogle Scholar
• Sundén M, Hermansson C, Taflin H, et al. Surgical treatment of breast cancer liver metastases - A nationwide registry-based case control study. Eur J Surg Oncol. 2020;46:1006–1012.
   PubMed Web of Science ®Google Scholar
• Muslu Ü. The evolution of breast reduction publications: a bibliometric analysis. Aesthetic Plast Surg. 2018;42:679–691.
   PubMed Web of Science ®Google Scholar
• Begum M, Lewison G, Jassem J, et al. Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: implications for future national cancer control planning. Eur J Cancer. 1990;2018(104):127–136.
   Google Scholar
• Wallin JA. Bibliometric methods: pitfalls and possibilities. Basic Clin Pharmacol Toxicol. 2005;97:261–275.
   PubMed Web of Science ®Google Scholar
• Wang Z, Huang C, Li X. Research trends and hotspot analysis of conjunctival bacteria based on citespace software. Biomed Res Int. 2020;2020:2580795.
   PubMed Web of Science ®Google Scholar
• Ahn SK, Hwang JW. Global trends in immunotherapy research on breast cancer over the past 10 years. J Oncol. 2020;2020:4708394.
   PubMed Web of Science ®Google Scholar
• Chong Y, Han C, Li J, et al. Mapping global research trends in stem cell therapy for inflammatory bowel disease: a bibliometric analysis from 1991 to 2019. J Int Med Res. 2020;48:300060520965824.
   PubMed Web of Science ®Google Scholar
• Avcu G, Sahbudak Bal Z, Duyu M, et al. Thanks to trauma: a delayed diagnosis of pott disease. Pediatr Emerg Care. 2015;31:e17–8.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Lewison G, Idir S, et al. The state of lung cancer research: a global analysis. J Thorac Oncol. 2016;11:1040–1050.
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–538.
   PubMed Web of Science ®Google Scholar
• Xie L, Chen Z, Wang H, et al. Bibliometric and visualized analysis of scientific publications on atlantoaxial spine surgery based on web of science and VOSviewer. World Neurosurg. 2020;137:435-442.e4.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–5391.
   PubMed Web of Science ®Google Scholar
• Guo S, Wang L, Xie Y, et al. Bibliometric and visualized analysis of stem cells therapy for spinal cord injury based on web of science and citespace in the last 20 years. World Neurosurg. 2019;132:e246–e58.
   PubMed Web of Science ®Google Scholar
• Said R, Hong DS, Warneke CL, et al. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013;4:705–714.
   PubMedGoogle Scholar
• Adam R, Aloia T, Krissat J, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897–907. discussion −8.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Vitale A, Bagante F, et al. Liver resection for breast cancer liver metastases: a cost-utility analysis. Ann Surg. 2017;265:792–799.
   PubMed Web of Science ®Google Scholar
• He X, Zhang Q, Feng Y, et al. Resection of liver metastases from breast cancer: a multicentre analysis. Clin Transl Oncol. 2020;22:512–521.
   PubMed Web of Science ®Google Scholar
• Xiao W, Zheng S, Yang A, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018;10:5329–5338.
   PubMed Web of Science ®Google Scholar
• Yu P, Liu P, Li N, et al. Hepatitis B virus infection specially increases risk of liver metastasis in breast cancer patients: a propensity-matched analysis. 2020;9(3):1506–1517.
   Google Scholar
• Hoshino A, Costa-Silva B, Shen TL, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527:329–335.
   PubMed Web of Science ®Google Scholar
• Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544.
   PubMed Web of Science ®Google Scholar
• Aktas BY, Taban H, Aksoy S. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2019;380:985–986.
   PubMed Web of Science ®Google Scholar
• Frentzas S, Simoneau E, Bridgeman VL, et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016;22:1294–1302.
   PubMed Web of Science ®Google Scholar
• Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.
   PubMed Web of Science ®Google Scholar
• Ge QD, Lv N, Kong YN, et al. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. Asian Pac J Cancer Prev. 2012;13:5081–5086.
   PubMed Web of Science ®Google Scholar
• Goddard ET, Hill RC, Nemkov T, et al. The rodent liver undergoes weaning-induced involution and supports breast cancer metastasis. Cancer Discov. 2017;7:177–187.
   PubMed Web of Science ®Google Scholar
• Tang C, Liu D, Fan Y, et al. Visualization and bibliometric analysis of cAMP signaling system research trends and hotspots in cancer. J Cancer. 2021;12:358–370.
   PubMed Web of Science ®Google Scholar
• Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel). 2019;11(9):1341.
   Google Scholar
• Adam R, Chiche L, Aloia T, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524–535.
   PubMed Web of Science ®Google Scholar
• Charalampoudis P, Mantas D, Sotiropoulos GC, et al. Surgery for liver metastases from breast cancer. Future Oncol. 2015;11:1519–1530.
   PubMed Web of Science ®Google Scholar
• Ruiz A, Castro-Benitez C, Sebagh M, et al. Repeat hepatectomy for breast cancer liver metastases. Ann Surg Oncol. 2015;22(Suppl 3):S1057–66.
   PubMed Web of Science ®Google Scholar
• Er O, Frye DK, Kau SW, et al. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J. 2008;14:62–68.
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2006;97:237–244.
   PubMed Web of Science ®Google Scholar
• Lindgaard SC, Brinch CM, Jensen BK, et al. Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer. Breast. 2019;43:113–119.
   PubMed Web of Science ®Google Scholar
• Hsiao JH, Chang HT, Tseng YD, et al. Hepatic arterial infusion chemotherapy is a feasible treatment option for breast cancer with liver-predominant metastatic disease. Vivo (Athens, Greece). 2018;32:1635–1641.
   PubMed Web of Science ®Google Scholar
• Klimanov MY, Syvak LA, Orel VE, et al. Efficacy of combined regional inductive moderate hyperthermia and chemotherapy in patients with multiple liver metastases from breast cancer. Technol Cancer Res Treat. 2018;17:1533033818806003.
   Web of Science ®Google Scholar
• Poon RT. Is radiofrequency ablation the treatment of choice for patients with small hepatocellular carcinoma? Nat Clin Pract Gastroenterol Hepatol. 2008;5:492–493.
   PubMedGoogle Scholar
• Kucharczyk MJ, Parpia S, Walker-Dilks C, et al. Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164:13–25.
   PubMed Web of Science ®Google Scholar
• Kümler I, Parner VK, Tuxen MK, et al. Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer. Radiol Med. 2015;120:536–541.
   PubMed Web of Science ®Google Scholar
• Meloni MF, Andreano A, Laeseke PF, et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation–intermediate and long-term survival rates. Radiology. 2009;253:861–869.
   PubMed Web of Science ®Google Scholar
• Carrafiello G, Fontana F, Cotta E, et al. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases. Radiol Med. 2011;116:1059–1066.
   PubMed Web of Science ®Google Scholar
• Taşçi Y, Aksoy E, Taşkın HE, et al. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB. 2013;15:789–793.
   PubMed Web of Science ®Google Scholar
• Veltri A, Gazzera C, Barrera M, et al. Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC): an adjunctive tool in the multimodal treatment of advanced disease. Radiol Med. 2014;119:327–333.
   PubMed Web of Science ®Google Scholar
• Fendler WP, Lechner H, Todica A, et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med. 2016;57:517–523.
   PubMed Web of Science ®Google Scholar
• Pieper CC, Meyer C, Wilhelm KE, et al. Yttrium-90 radioembolization of advanced, unresectable breast cancer liver metastases-A single-center experience. JVIR. 2016;27:1305–1315.
   Web of Science ®Google Scholar
• Cianni R, Pelle G, Notarianni E, et al. Radioembolisation with (90) Y-labelledresin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol. 2013;23:182–189.
   PubMed Web of Science ®Google Scholar
• Feretis M, Solodkyy A. Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: a systematic review. World J Gastrointest Oncol. 2020;12:228–236.
   PubMed Web of Science ®Google Scholar
• Cheng B, Sethi I, Davisson N, et al. Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer. Nucl Med Commun. 2021;42:402–409.
   PubMed Web of Science ®Google Scholar
• Fu Y, Ling Z, Arabnia H, et al. Current trend and development in bioinformatics research. BMC Bioinformatics. 2020;21:538.
   PubMed Web of Science ®Google Scholar
• Bertucci F, Ng CKY, Patsouris A, et al. Author correction: genomic characterization of metastatic breast cancers. Nature. 2019;572:E7.
   PubMed Web of Science ®Google Scholar
• Lin X, Hong S, Chen J, et al. The potential targets for metastases: a study on altered circular RNA profile in breast cancer liver metastases. Epigenomics. 2019;11:1237–1250.
   PubMed Web of Science ®Google Scholar
• Zhu X, Huang R, Hu P, et al. Prognostic factors for survival in patients with malignant giant cell tumor of bone: a risk nomogram analysis based on the population. Med Sci Monit. 2021;27:e929154.
   PubMed Web of Science ®Google Scholar
• Lin Z, Yan S, Zhang J, et al. A nomogram for distinction and potential prediction of liver metastasis in breast cancer patients. J Cancer. 2018;9:2098–2106.
   PubMed Web of Science ®Google Scholar
• Zhao W, Wu L, Zhao A, et al. A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study. BMC Cancer. 2020;20:982.
   PubMed Web of Science ®Google Scholar
• Ji L, Fan L, Zhu X, et al. A prognostic model for breast cancer with liver metastasis. Front Oncol. 2020;10:1342.
   PubMed Web of Science ®Google Scholar
• Tan WW, Allred JB, Salim M, et al. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012;12:81–86.
   PubMed Web of Science ®Google Scholar
• Wilks S, Puhalla S, O’Shaughnessy J, et al. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer. Clin Breast Cancer. 2014;14:405–412.
   PubMed Web of Science ®Google Scholar
• Chen QF, Huang T, Shen L, et al. Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: a competing risk analysis. Mol Clin Oncol. 2019;11:259–269.
   PubMed Web of Science ®Google Scholar
• Chun YS, Mizuno T, Cloyd JM, et al. Hepatic resection for breast cancer liver metastases: impact of intrinsic subtypes. Eur J Surg Oncol. 2020;46:1588–1595.
   PubMed Web of Science ®Google Scholar